QuidelOrtho (QDEL) EBIAT (2021 - 2025)
QuidelOrtho (QDEL) has disclosed EBIAT for 5 consecutive years, with -$130.7 million as the latest value for Q4 2025.
- Quarterly EBIAT rose 26.74% to -$130.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.1 billion through Dec 2025, up 44.84% year-over-year, with the annual reading at -$1.1 billion for FY2025, 44.84% up from the prior year.
- EBIAT hit -$130.7 million in Q4 2025 for QuidelOrtho, up from -$733.0 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $479.9 million in Q2 2022 to a low of -$1.7 billion in Q1 2024.
- Historically, EBIAT has averaged -$155.9 million across 5 years, with a median of -$16.3 million in 2023.
- Biggest five-year swings in EBIAT: skyrocketed 232.98% in 2022 and later plummeted 3595.9% in 2024.
- Year by year, EBIAT stood at $215.7 million in 2021, then plummeted by 91.1% to $19.2 million in 2022, then tumbled by 2852.6% to -$528.5 million in 2023, then soared by 66.24% to -$178.4 million in 2024, then grew by 26.74% to -$130.7 million in 2025.
- Business Quant data shows EBIAT for QDEL at -$130.7 million in Q4 2025, -$733.0 million in Q3 2025, and -$255.4 million in Q2 2025.